Document is current
Any future updates will be listed below
-
Authors
Allajbeu, Iris
Nanaa, Muzna
Manavaki, Roido
Papalouka, Vasiliki
Bene, Ioana
Payne, Nicholas
Giannotti, Elisabetta
van Nijnatten, Thiemo
Kilburn-Toppin, Fleur
Healy, Nuala
Gilbert, Fiona https://orcid.org/0000-0002-0124-9962
-
Funding
Funding for this research was provided by:
National Institute for Health Research Health Protection Research Unit
Cancer Research UK
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 6 January 2025
Accepted: 7 February 2025
First Online: 3 April 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Professor Fiona J. Gilbert.
: The authors of this manuscript declare relationships with the following companies: GE Healthcare and Bayer.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained. Ethical approval was obtained from a National Research Ethics Committee: 1. CONTEND; REC Reference Number:15/EE/0279. 2. BRAID REC Reference Number:19/LO/0350.
: Initial findings from this study have been presented as a research presentation at ECR Vienna, Austria, 2022 (Allajbeu et al, ‘Quantification of enhancement intensity and patterns of benign and malignant lesions in contrast-enhanced spectral mammography and its correlation with magnetic resonance imaging enhancement patterns’).
:
